Jonathan Mozena, MD
Allergy & Immunology · Fredericksburg, VANPI 1093757163
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,485 of the $13,903 with a category attached, or 61.0%. 30 manufacturers reported payments, led by AstraZeneca at 58.1% of the total. 2025 is the largest year on record at $7,388, 5.3 times the $1,401 reported in 2019.
Across 404 payments — averaging $34.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- GSK$1K
- Sanofi$509
- Regeneron Healthcare Solutions, Inc.$479
- Novartis$448
- CSL Behring$440
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$5,40039%
- Food & beverage$8,48561%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 119 | $8,076 |
| GSK | 76 | $1,471 |
| Sanofi | 23 | $509 |
| Regeneron Healthcare Solutions, Inc. | 26 | $479 |
| Novartis | 23 | $448 |
| CSL Behring | 17 | $440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $394 |
| Genentech USA, Inc. | 23 | $311 |
| Amgen(2 entities) | 16 | $283 |
| Blueprint Medicines Corporation | 6 | $247 |
| Grifols USA, LLC | 10 | $230 |
| Incyte Corporation | 6 | $148 |
| Pfizer | 6 | $130 |
| Biocryst US Sales Co., LLC | 4 | $129 |
| Optinose US, Inc. | 7 | $125 |
| Shire North American Group Inc | 4 | $89 |
| Kaleo, Inc. | 4 | $64 |
| Ionis Pharmaceuticals, Inc. | 2 | $42 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $40 |
| Pharming Healthcare, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Biocryst Pharmaceuticals, Inc. | 2 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Boehringer Ingelheim | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
| Alk-abello, Inc | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,903 in reported general payments places this provider in the 75th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 15 | $61,476 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $51,016 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $29,847 |
| Epinephrine | 71 | $12,419 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,784 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $4,936 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $3,062 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $1,872 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 16 | $1,650 |
| Mometasone Furoate | 20 | $1,543 |
| Ipratropium Bromide | 38 | $1,296 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,248 |
| Levocetirizine Dihydrochloride | 59 | $1,237 |
| Montelukast Sodium | 99 | $759 |
| Triamcinolone Acetonide | 13 | $255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,471 | $80,86395 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $8,076 | $68,26026 claims |
| Hikma Pharmaceuticals USAEpinephrine | $13 | $12,41971 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $33 | $3,06212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 133 allergy & immunology providers in Virginia.
Other allergy & immunology in Fredericksburg
- Andrew KimFredericksburg$104K
- Ahmed ButtFredericksburg$59K
- Julie AbrahamFredericksburg$11K
- Jonathon PosthumusFredericksburg$9K
- Charles LaneLynchburg$1.4M
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Courtney BlairMc Lean$139K
- Behnam DaghighLeesburg$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.